UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2540-2547

2013

Link zum Volltext

Verfügbarkeit prüfen

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Histopathology, 2011-01, Vol.58 (1), p.90-105

de Tute, Ruth M

2011

Link zum Volltext

Verfügbarkeit prüfen

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2889-2900

2022

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3945

2023

Link zum Volltext

Verfügbarkeit prüfen

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.31-39

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.61-72

2016

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

The New England journal of medicine, 2008-08, Vol.359 (6), p.575-583

2008

Link zum Volltext

Verfügbarkeit prüfen

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.54-60

2016

Link zum Volltext

Verfügbarkeit prüfen

Reply to M. Roschewski et al

Journal of clinical oncology, 2014-02, Vol.32 (5), p.476-477

2014

Link zum Volltext

Verfügbarkeit prüfen

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Blood, 2022-11, Vol.140 (Supplement 1), p.7032-7033

2022

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic control of the protocadherin-gamma locus provides a potential source of cell surface codes in B cell differentiation

The Journal of immunology (1950), 2020-05, Vol.204 (1_Supplement), p.153-153.17

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Blood, 2022-11, Vol.140 (Supplement 1), p.3624-3626

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Blood, 2022-11, Vol.140 (Supplement 1), p.12626-12627

2022

Link zum Volltext

Verfügbarkeit prüfen

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.1371-1372

2022

Link zum Volltext

Verfügbarkeit prüfen

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.820-820

2021

Link zum Volltext

Verfügbarkeit prüfen

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8001-8001

2021

Link zum Volltext

Verfügbarkeit prüfen

A Review of Flow Cytometry and its Use in the Diagnosis and Management of Mature Lymphoid Malignancies

Histopathology, 2011-01, Vol.58 (1)

de Tute, Ruth

2011

Link zum Volltext

Verfügbarkeit prüfen

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies: Use of flow cytometry in the context of mature lymphoid malignancies

Histopathology, 2011-01, Vol.58 (1), p.90-105

de Tute, Ruth M

2011

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Blood, 2020-11, Vol.136 (Supplement 1), p.27-28

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 83

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(83)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Multiple Myeloma - Drug Therapy
(8)
Female
(6)
Flow Cytometry
(6)
Multiple Myeloma
(6)
Oncology
(6)
Pathology
(6)
Aged
(5)
Male
(5)
Medical Laboratory Technology
(5)
Multiple Myeloma - Diagnosis
(5)
Prognosis
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Middle Aged
(4)
Multiple Myeloma - Mortality
(4)
Neoplasm, Residual - Drug Therapy
(4)
Remission Induction
(4)
Survival Analysis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Reply to M. Roschewski et al

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Epigenetic control of the protocadherin-gamma locus provides a potential source of cell surface codes in B cell differentiation

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

A Review of Flow Cytometry and its Use in the Diagnosis and Management of Mature Lymphoid Malignancies

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies: Use of flow cytometry in the context of mature lymphoid malignancies

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Aktive Filter

Suchergebnisse filtern